Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx věcí,

kterým xx mění a xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo zahraničních xxxx sděluje, xx xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx nového xxxxx Xxxxxxx X - Xxxxxx zakázaných látek x xxxxx xxxxxxx xxx rok 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu.

S xxxxx xxxxxx Xxxxxxx X vyslovil xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x prezident xxxxxxxxx xxxxxxxx xxxxxxx o xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, pro Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X pro xxx 2023, xxxxxxx od 1. ledna 2023, xxxxx xxxxxxxxx x xxxxxxxx pro Xxxxxx xxxxxxxxx dne 22. xxxxxx 2023 x xxxx vyhlášena xxx č. 32/2023 Sb. m. s.

Xxxxxxxx znění Xxxxxxx X xxx rok 2024 a její xxxxxxx do xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. JUDr. Xxxxxx, Xx.X., LL.M., x. x.

xxxxxx ředitel xxxxx xxxxxx a xxxxxxxxxx
&xxxx;

Xxxxxxx č. 1

Xxxxxxx xxxxxxxxxxx smlouvy xx xxxxxxx xxxxxx

Xxxx

Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx standard x xxxxx Světového xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx je každoročně xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx procesu zprostředkovaném Xxxxxxxx antidopingovou agenturou (XXXX). Seznam xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx zakázaných xxxxx x xxxxx xxxx xxxxxxxxx XXXX x xxxx publikován x xxxxxxxxxx a xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx mezi xxxxxxxxx x francouzským textem xxxxxxxxx znění x xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx pojmy xxxxxxxxx x xxxxx Seznamu xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Při xxxxxxx

Xxxxx XXXX pro daný xxxxx xxxxxxxxxxx xxxx xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx začínajícím xxxxx před xxxxxxx (xx 23:59 hodin) x xxx xxxxxxxxxxxxx Xxxxxxx, které xx xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx a xxxxxxx xxxxxx Vzorku.

Zakázané xxxxx

Xx xxxxxxx, xx daná xxxxx xxxx metoda xx zakázána Při xxxxxxx x Xxxx xxxxxx, xxx xx xxxxxxxxxx v Kodexu.

Specifické x Nespecifické

Podle xxxxxx 4.2.2 Xxxxxxxxx antidopingového Xxxxxx „pro účely xxxxxxxx článku 10 xxxxx všechny Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx xxxx xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx a xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx metodou, xxxxx xxxx v Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx k xxxxxx „Xxxxxxxxxx látky x Xxxxxxxxxx xxxxxx xxxxxxx x xxxxxx 4.2.2 xx xxxxxx být xxxxxx způsobem xxxxxxxxxx xx xxxx xxxxxxxx xxxx xxxx xxxxxxxxxx xxx xxxx xxxxxxxxx xxxxx xxxx xxxxxx. Xxx xxxxx x xxxxx a xxxxxx, xxxxx Sportovec xxxxxxxxxxxxx xxxx xxxx použil x xxxxxx účelu xxx xx zlepšení xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Návykové xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx xxxx jako xxxxxx označeny z xxxxxx xxxxxx xxxxxxx xxxxxxxxxx ve společnosti xxxx rámec xxxxxx. Xxxx Návykové xxxxx xxxx xxxxxxxxxx tyto xxxxx: xxxxxx, diamorfin (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX STÁLE (PŘI XXXXXXX I MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x této třídě xxxx Xxxxxxxxxx látky.

Jakákoliv xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx nevztahuje xxxxx z xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx není v xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx x xxxx (např. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx vývoji nebo xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx schválené xxxxx xxx xxxxxxxxxxx použití), xx xxxxxxxx xxxxx.

Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, mimo xxxx BPC-157, 2,4-xxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxx (xxxx. Xxxxxxxxxxx x Xxxxxxxxxx).

X1 XXXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx jsou xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx xxxxxxxxx xxxxxx, xxxx xxxx včetně:

•	1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion)		•	furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on)		•	mesterolon
•	4-androstenediol (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on)
•	4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on)		•	metenolon
•	5-androstenedion (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-hydroxy-5ɑ-androstan-3-on)		•	nandrolon (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on)		•	prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)		•	testosteron
•	epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x další xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx biologickými xxxxxx.

X1.2. XXXXXXX XXXXXXXXXX LÁTKY

Mimo xxxx xxxxxx:

Xxxxxxxxxxx, osilodrostat, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx [SARM, xxxx. andarin, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, X-23 a XX-11], xxxxxxx x xxxxxxxxxx.

X2 PEPTIDOVÉ HORMONY, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X MIMETIKA

ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X MIMO XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxx x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx jsou xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X LÁTKY OVLIVŇUJÍCÍ XXXXXXXXXXX

Xxxx jiné xxxxxx:

X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. darbepoetiny (xXXX); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); roxadustat (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx GATA, xxxx. X-11706.

X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), např. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo EPO; xxxxxxxxxxxxx XXX (CEPO).

S2.2. XXXXXXXXX HORMONY X XXXXXX UVOLŇUJÍCÍ XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, mimo xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (XX),

• xxxxxxxxxxxx xxxxxx (XX),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) x jeho xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x triptorelin),

 • xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Kortikotropiny x xxxxxx xxxxxxxxxx faktory, xxxx. kortikorelin x xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx hormon (XX), xxxx xxxxxxx x xxxxxxxxx, xxxx xxxx včetně:

• analogy xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, somapacitan x xxxxxxxxxx,

• xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x xXX 176–191.

S2.2.4 Xxxxxxx uvolňující růstový xxxxxx, xxxx xxxx xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x jeho xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx a xxxxxxxxxxx,

• xxxxxxxxxxx růstového xxxxxxx (XXX) a xxxxxx xxxxxxxx [např. anamorelin, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x tabimorelin],

• xxxxxxx xxxxxxxxxx XX (XXXX) [xxxx. alexamorelin, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX RŮSTOVÝCH XXXXXXX

Xxxx jiné xxxxxx:

• xxxxxxxxxxxxx růstové faktory (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (HGF)

• růstový xxxxxx 1 podobný xxxxxxxx (XXX-1, xxxxxxxxxx) x xxxx xxxxxxx

• xxxxxxxxxx růstové faktory (XXX)

• xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF)

• xxxxxxxx-β4 x xxxx xxxxxxxx, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (VEGF)

a xxxxx xxxxxxx faktory xxxx modulátory xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx ve svalech, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 BETA-2 XXXXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky v xxxx xxxxx xxxx Xxxxxxxxxx látky.

Všichni xxxxxxxxxx x xxxxxxxxxxxx beta-2 xxxxxxxx xxxxxx všech xxxxxxxxx xxxxxxx xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx salbutamol: xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 hodin xx xxxxxxxxx dávce;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• inhalační xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: maximálně 25 xxxxxxxxxx xx 24 hodin.

POZNÁMKA

Přítomnost xxxxxxxxxxx x moči x xxxxxxxx xxxxxx než 1000 ng/ml xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxxx x xxxx xxxxxxxxxx za Xxxxxxxxx laboratorní xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, že xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx dávky (inhalační) xx do výše xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I MIMO XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx S4.1 a X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx xx xxxx X4.3 a X4.4 xxxx Nespecifické xxxxx.

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. INHIBITORY AROMATÁZ

Mimo xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on)		•	androsta-3,5-dien-7,17-dion (arimistan)
•	3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)		•	formestan
•	4-androsten-3,6,17 trion (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX ESTROGENOVÝCH RECEPTORŮ (XXXXX)]

Xxxx xxxx včetně:

•	arformoterol		•	indakaterol		•	reproterol		•	tretoquinol (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. LÁTKY ZABRAŇUJÍCÍ XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx včetně:

•	protilátky xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, např.:
•	konkurenty receptoru xxxxxxxx XXX, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx
	- xxxxxxx receptory xxxxxxxx (xxxx. XXX-031)			- xxxxxxxx xxxxxx myostatin (xxxx. xxxxxxxxxxx, propeptid myostatinu)
•	protilátky xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (např. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, stamulumab)

S4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, xxxxxxxx peroxizomovými xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, GW501516) x agonisté Xxx-xxxɑ , xxxx. XX9009, XX9011

X4.4.2 insuliny x xxxxxxxx insulinů

S4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX A XXXXXXXXX LÁTKY

ZAKÁZANÉ STÁLE (XXX SOUTĚŽI I XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx x xxxxxxxxx látky, xxxxxx xxxxx optických xxxxxxx, xxxx. x- a x-, xxxx xxxxxxxx.

Xxxx xxxx včetně:

•  Xxxxxxxxx, xxxx např.:

acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; spironolakton; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x hydrochlorothiazid; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. xxxxxxxxxx, mozavaptan, xxxxxxxxx;

• Plazmatické xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:

xxxxxxx, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;

• Xxxxxxxxxxx;

• Probenecid;

a xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• drospirenon; xxxxxxxx; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxxx);

• xxxxxxx xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx množství xxxxx xx stanoveným prahovým xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, katinu, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Vzorku Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx jinou xxxxxxxxx xxxxxx (xxxxx lokálního xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxx lokálního xxxxxx xxxxxxxxxxx v xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec nemá xxxxxxxxxx Terapeutickou xxxxxxx (XX) na xxxx xxxxx xxxxx x xx, xxxxx již xxxx xxxxxxx xx xxxxxxxxxx nebo xxxxx xxxxxxxxx látku.

ZAKÁZANÉ XXXXXX

XXXXXXXX XXXXX (PŘI SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx v xxxx třídě jsou Xxxxxxxxxxxx x výjimkou xxxxx x X2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X1.1. Xxxxxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx heterologní xxxx xxxx produktů x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx s xxxxxxxx xxxxxxxx xxxxxx nebo xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx odběrovém xxxxxx.

X1.2. Xxxxx zvyšování xxxxxx, přenosu xxxx xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, např. xxxxxx xxxxxxxx xx xxxx xxxxxxxxxxx a xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x výjimkou doplňkového xxxxxxx xxxxxxxx.

X1.3. Jakákoliv xxxxx xxxxxxxxxxxxxxx manipulace x xxxx nebo x krevními xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Podvádění xxxx Xxxxx x podvod xx účelem porušit xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Vzorku.

M2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více xxx xxxxxx 100 xx xx 12 hodin xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx ošetření, chirurgických xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx vyšetření.

M3. XXXXXX X BUNĚČNÝ XXXXXX

X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx jiné xxxxxxxx xxxxxxxxxxx úprav xxxx, umlčování xxxx x xxxxxxxxxxx přenosů xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x této třídě xxxx Xxxxxxxxxx xxxxx x xxxxxxxx látek xxxxxxxxx x X6.X, xxx xxxx Nespecifické xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx všech xxxxxxxxx xxxxxxx, např. x- x x-, xxxx zakázána.

Stimulancia zahrnují:

S6.A: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx uveden x xxxxx xxxxxx, je Xxxxxxxxxxx xxxxxx.

X6.X: SPECIFICKÁ XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, BMPEA)		•	famprofazon		•	oktopamin
•	3-metylhexan-2-amin (1,2-dimetylpentylamin)		•	fenbutrazát		•	oxilofrin (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx x xxxx analogy, např. xxxxxxxx, xxxxxxxx a ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (dimetylamfetamin)		•	metylendioxymetamfetamin		•	selegilin
•	efedrin3)		•	metylefedrin3)		•	sibutramin
•	epinefrin (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát]		•	solriamfetol
•	etamivan		•	metylfenidát		•	strychnin
•	etylfenidát		•	niketamid		•	tenamfetamin (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx účinky

VÝJIMKY

• xxxxxxxx;

• xxxxxxxx imidazolinu x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, očního nebo xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, klonazolin, fenoxazolin, xxxxxxxxxxx, xxxxxxxxx, oxymetazolin, xxxxxxxxxx, tramazolin, xylometazolin) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Specifické xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x l, jsou xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx a xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx. Xxxxxxxx látky x této sekci: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xxxx.

• x xxxxxx (hašiš, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• xxxxxxxx a xxxxxxxxxx tetrahydrokanabionoly (THC)

• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx třídě jsou Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx zakázány, xxxxx xxxx podávány jakoukoliv xxxxxxxx, perorální [včetně xxxxxxxxxx (xxxx. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx podání (včetně xxxxxxxxxxx x topického: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx a xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx xx xxxxxxxxx x rámci xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX SPORTECH

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx a kde xx xx xxxxxxxx xxxxxxxx (*) i Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• lyžování/snowboarding (XXX) – xxxxx na xxxxxx, xxxxxxxxxxx xxxxx / U-rampa x xxxxxxxxx X-xxxxx / xxx xxx

• automobilový xxxxx (XXX)

• xxxxxxxx xxxxxx (XXXX)* v xxxxxxxxxxxx volného xxxxxxxx, xxxx xxxxxxxx a xxxxxxx xx terč

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• xxxxx (XXX)

• xxxx (XXX)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx xxxxxx

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx smlouvy x xxxxxxxxx jazyce
 

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) a jeho x-xxxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx x moči xxxxx xxx 5 xxxxxxxxxx x 1 ml.

²⁾ xxxxxxxxxxxxx: zakázaný pouze xxx xxxxxxxxxxx x xxxx xxxxx než 150 mikrogramů x 1 xx.

³⁾ xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 xxxxxxxxxx v 1 xx.

⁴⁾ xxxxxxxxx (xxxxxxxxx): není zakázáno xxxxxxx xxxxxxxx, xxxx. xxxxx, oční, xxxx xxxxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, pipradrol x xxxxxxxx: xxxx xxxxx xxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx považovány xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 19/2025 Xx. xxxxx xxxxxxxxx xxxx 28.1.2024.

Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx